Cargando…

Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines

BACKGROUND:  Determining background rates of medical conditions identified as adverse events of special interest (AESI) that may occur following COVID-19 vaccination is important for contextualising and investigating potential vaccine safety signals. METHODS: We conducted a retrospective population-...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillsbury, Alexis, Phillips, Anastasia, Deng, Lucy, Quinn, Helen, Macartney, Kristine, Gidding, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110935/
https://www.ncbi.nlm.nih.gov/pubmed/37088604
http://dx.doi.org/10.1016/j.vaccine.2023.04.041
_version_ 1785027351069851648
author Pillsbury, Alexis
Phillips, Anastasia
Deng, Lucy
Quinn, Helen
Macartney, Kristine
Gidding, Heather
author_facet Pillsbury, Alexis
Phillips, Anastasia
Deng, Lucy
Quinn, Helen
Macartney, Kristine
Gidding, Heather
author_sort Pillsbury, Alexis
collection PubMed
description BACKGROUND:  Determining background rates of medical conditions identified as adverse events of special interest (AESI) that may occur following COVID-19 vaccination is important for contextualising and investigating potential vaccine safety signals. METHODS: We conducted a retrospective population-based cohort study using linked emergency department, hospitalisation and death data for 2017 and 2018 from Australia’s most populous state, New South Wales. Incident cases of select neurological conditions, arterial or venous thromboembolic conditions, secondary thrombocytopenia, myocarditis/pericarditis, and unique events of anaphylaxis and generalised convulsions were identified using internationally agreed upon diagnostic (ICD-10) codes. State-specific rates per 100,000 person-years were calculated, with further stratification by age group and sex where clinically relevant to the condition, and the number of expected cases nationally in one and 6 weeks was estimated. RESULTS: Background rates of selected neurological conditions were low with the exception of generalised convulsions for which 1,599–1,872 cases were estimated nationally in a 1-week period in the absence of vaccination. Using a narrow case definition, rates of Guillain-Barré Syndrome (3.9 per 100,000 person-years) were higher than international rates reported elsewhere. Thromboembolic and cerebral venous sinus thrombosis event rates increased with age. Myocarditis occurred more commonly in males, and was highest in males aged 18–24 years, with an estimated 1–4 cases expected nationally in a 1-week period. CONCLUSIONS: Using routinely collected linked healthcare data provides localised estimates of background rates of new onset or periodic AESI which enables rapid estimation of observed-versus-expected rates of events reported following COVID-19 vaccination. This Australian-specific analysis contributes AESI background rates which can be compared with those from other countries to enhance understanding of geographic variability in the frequency of specific AESI in the absence of vaccination, and can be utilised for signal detection during program implementation.
format Online
Article
Text
id pubmed-10110935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101109352023-04-18 Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines Pillsbury, Alexis Phillips, Anastasia Deng, Lucy Quinn, Helen Macartney, Kristine Gidding, Heather Vaccine Article BACKGROUND:  Determining background rates of medical conditions identified as adverse events of special interest (AESI) that may occur following COVID-19 vaccination is important for contextualising and investigating potential vaccine safety signals. METHODS: We conducted a retrospective population-based cohort study using linked emergency department, hospitalisation and death data for 2017 and 2018 from Australia’s most populous state, New South Wales. Incident cases of select neurological conditions, arterial or venous thromboembolic conditions, secondary thrombocytopenia, myocarditis/pericarditis, and unique events of anaphylaxis and generalised convulsions were identified using internationally agreed upon diagnostic (ICD-10) codes. State-specific rates per 100,000 person-years were calculated, with further stratification by age group and sex where clinically relevant to the condition, and the number of expected cases nationally in one and 6 weeks was estimated. RESULTS: Background rates of selected neurological conditions were low with the exception of generalised convulsions for which 1,599–1,872 cases were estimated nationally in a 1-week period in the absence of vaccination. Using a narrow case definition, rates of Guillain-Barré Syndrome (3.9 per 100,000 person-years) were higher than international rates reported elsewhere. Thromboembolic and cerebral venous sinus thrombosis event rates increased with age. Myocarditis occurred more commonly in males, and was highest in males aged 18–24 years, with an estimated 1–4 cases expected nationally in a 1-week period. CONCLUSIONS: Using routinely collected linked healthcare data provides localised estimates of background rates of new onset or periodic AESI which enables rapid estimation of observed-versus-expected rates of events reported following COVID-19 vaccination. This Australian-specific analysis contributes AESI background rates which can be compared with those from other countries to enhance understanding of geographic variability in the frequency of specific AESI in the absence of vaccination, and can be utilised for signal detection during program implementation. Elsevier Ltd. 2023-05-22 2023-04-18 /pmc/articles/PMC10110935/ /pubmed/37088604 http://dx.doi.org/10.1016/j.vaccine.2023.04.041 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pillsbury, Alexis
Phillips, Anastasia
Deng, Lucy
Quinn, Helen
Macartney, Kristine
Gidding, Heather
Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
title Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
title_full Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
title_fullStr Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
title_full_unstemmed Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
title_short Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
title_sort background incidence rates of selected adverse events of special interest (aesi) to monitor the safety of covid-19 vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110935/
https://www.ncbi.nlm.nih.gov/pubmed/37088604
http://dx.doi.org/10.1016/j.vaccine.2023.04.041
work_keys_str_mv AT pillsburyalexis backgroundincidenceratesofselectedadverseeventsofspecialinterestaesitomonitorthesafetyofcovid19vaccines
AT phillipsanastasia backgroundincidenceratesofselectedadverseeventsofspecialinterestaesitomonitorthesafetyofcovid19vaccines
AT denglucy backgroundincidenceratesofselectedadverseeventsofspecialinterestaesitomonitorthesafetyofcovid19vaccines
AT quinnhelen backgroundincidenceratesofselectedadverseeventsofspecialinterestaesitomonitorthesafetyofcovid19vaccines
AT macartneykristine backgroundincidenceratesofselectedadverseeventsofspecialinterestaesitomonitorthesafetyofcovid19vaccines
AT giddingheather backgroundincidenceratesofselectedadverseeventsofspecialinterestaesitomonitorthesafetyofcovid19vaccines